FGFR1 and neoplasm: Specifically, the use of the eIF4A inhibitor Zotatifin in TNBC mouse models suppressed the translation of Sox4 and Fgfr1, resulting not only in the inhibition of cell proliferation but also in increased interferon response and remodeling of the tumor immune microenvironment.